Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4134 Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumors in the lungNENomics project

Introduction: The lungNENomics project analysed 300 lung neuroendocrine tumors (NETs), of which 259 cases were pathologically reviewed by six expert pathologists.

Conference:

Presenting Author: Mathian E

Authors: Mathian E, Drouet Y, Sexton-Oates A, Papotti M, Pelosi G,

Keywords: Lung neuroendocrine neoplasm, Pathology, Deep-learning, Ki-67, PHH3,

#675 Olfactory Receptor 51E1 is a Potential Novel Target for Diagnosis and Treatment of Somatostatin Receptor Negative Lung Carcinoid Patients

Introduction: Somatostatin receptor (SSTR) expression may be used for diagnosis and therapy of lung carcinoids. However, novel targets are requested.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Cui T

Authors: Cui T, Giandomenico V, Öberg K, Pelosi G, Tsolakis A,

Keywords: olfactory receptor 51E1, somatostatin receptor, lung carcinoids, novel target, OctreoScan,

#364 Platinum-based chemotherapy in patients with advanced neuroendocrine carcinomas: an Italian retrospective multicenter analysis

Introduction: Conventional chemotherapy has not yet a well defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs).

Conference:

Presenting Author:

Authors: SPADA F, SCARABELLI L, LORIZZO K, PELOSI G, BARBERIS M,

Keywords: neuroendocrine, ERCC1, Ki 67 ,

#144 Oxaliplatin-based chemotherapy in patients with advanced neuroendocrine carcinoma: an Italian retrospective multicenter analysis

Introduction: Conventional chemotherapy does not have a well-defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs). Various regimens were evaluated. Cisplatin or carboplatin combined with etoposide are usually indicated in poorly differentiated (PD) NECs. Some evidence exists for oxaliplatin activity in WD and PD NECs, combined with capecitabine or gemcitabine.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Spada F

Authors: Spada F, Nobili E, Ricasoli M, Scarabelli L, Pelosi G,

Keywords: neuroendocrine tumors, oxaliplatin, ERCC1, Ki 67 ,